Michigan Accelerator Fund I Invests $750,000 in Swift Biosciences
News Jan 18, 2013
Michigan Accelerator Fund I has made a $750,000 Series A1 investment in Swift Biosciences Inc.
This is the seventh company MAF 1 has funded since the fund’s inception in 2010, and the first investment since the fund closed at $15.1 million in August 2012.
The investment in Swift Biosciences continues MAF 1’s strategic focus to invest in Michigan-based, early stage, life science technology companies.
Located in Ann Arbor, Swift Biosciences is commercializing genetic testing technology to advance the field of genomics and personalized medicine. To date, Swift has launched a product suite referred to as myT Primers, which enable detection of mutated cells related to melanoma with extreme sensitivity. This opens the door for test specimens to be collected as blood samples instead of tissue, which may allow for earlier detection. In 2013, Swift will launch a new line of products focused on genome sequencing.
“We are thrilled to be investing in Swift at an extremely timely juncture, as their technology is forecast to hit the market right when the need will be the greatest,” said Dale Grogan, managing director of MAF 1. “We look forward to our investment realizing solid returns in two to three years, if not sooner.”
Launched in 2010 with the backing of several Michigan-based individual investors, MAF 1 now joins Houston-based Mercury Fund as Swift’s only institutional investors. The total invested in Swift to date is $6.15 million. The latest funding will support product development, patent filing and prosecution, and direct sales and marketing to key laboratory leaders.
“The inclusion of MAF 1 as a Michigan-based investor is highly encouraging, and provides us with additional financial runway as we launch new products in 2013,” said Swift Biosciences CEO David Olson. “They are a welcome addition to the Swift team.”
New Rapid Test for Valley Fever Should Help Reduce Diagnosis DelaysNews
November saw a spike if cases of Valley fever. Fortunately, the recent—and timely—approval of a new rapid assay test for Valley fever should reduce delays in diagnosing the respiratory fungal infections—a frequent problem in treating the disease, which is caused by spores endemic to soils in the U.S. Southwest.READ MORE
Single-stranded Origami Technology Drives Drug Delivery Systems and Pharmaceutical Nanofactories ForwardNews
First nanotechnological approach enables the design and replication of complex single-stranded DNA and RNA origami with potential for drug delivery and nanofabrication.READ MORE
Cracking the Code of Coenzyme Q BiosynthesisNews
Coenzyme Q is a vital cog in the body’s energy-producing machinery, a kind of chemical gateway in the conversion of food into cellular fuel. Researchers are developing new tools to shed light on CoQ function, primarily by finding and defining proteins that have a direct link to the chemical. This includes the development of a new multi-omic strategy to identify the global function of an RNA-binding protein that has long been associated with mitochondria and its role in CoQ biosynthesis.READ MORE